IPO - Oruka Therapeutics, Inc.

Form Type: POS AM

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025021251

Filing Summary: This document is a Post-Effective Amendment No. 1 to Form S-1 Registration Statement under the Securities Act of 1933 for Oruka Therapeutics, Inc. The company updated its registration statement to include financial statements for the fiscal year ended December 31, 2024, as well as updates based on its Form 10-K filed on March 6, 2025. The going public process is tied to the Merger Agreement with ARCA biopharma, Inc., completed on August 29, 2024. The prospectus includes the proposed resale of 8,719,000 shares of common stock by selling stockholders, with no new securities being offered by Oruka itself. The common stock trades on the Nasdaq Global Market under the symbol "ORKA." The proceeds from the sale will go to the selling stockholders, and Oruka will not receive any of the proceeds from the sale of shares under this prospectus. The document also emphasizes the investment risks including potential regulatory hurdles, and the company’s focus on developing monoclonal antibodies for psoriasis and other inflammatory conditions.

Document Link: View Document